In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.

Abstract

Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa are being isolated from patient specimens with increasing frequency in Latin America and worldwide. The current study provides an initial description of the in vitro activity of Imipenem/Relebactam (IMR) against non-Morganellaceae Enterobacterales (NME) and P. aeruginosa infecting hospitalized patients in Latin America. From2018to2020, 37clinical laboratories in nine Latin American countries participated in the SMART global surveillance program and contributed 15,466 NME and 3408 P aeruginosa isolates. MICs for IMR and seven comparators were determined using CLSI broth microdilution and interpreted by CLSI M100 (2022) breakpoints. β-lactamase genes were identified in selected isolate subsets. IMR (96.9%susceptible), amikacin(95.9%), meropenem(90.7%), and imipenem(88.7%) were the most active agents against NME. Among piperacillin/tazobactam-nonsusceptible NME (n = 4124), 90.4%of isolates were IMR-susceptible (range by country, 97.2[Chile] to67.0%[Guatemala]) and among meropenem-nonsusceptible NME isolates (n = 1433), 74.0%were IMR-susceptible (94.1%[Puerto Rico] to5.1% [Guatemala]). Overall, 6.3%of all collected NME isolates carried a KPC (metallo-β-lactamase [MBL]-negative), 1.8%an MBL, 0.4%an OXA-48-like carbapenemase (MBL-negative), and 0.1%a GES carbapenemase (MBL-negative). Amikacin (85.2%susceptible) and IMR (80.1%) were the most active agents against P. aeruginosa; only56.5% of isolates were imipenem susceptible. Relebactam increased susceptibility to imipenem by22.0% (from23.9%to45.9%) in piperacillin/tazobactam-nonsusceptible isolates (n = 1031) and by35.5%(from5.5%to41.0%) in meropenem-nonsusceptible isolates (n = 1128). Overall, 7.6%of all collected P. aeruginosa isolates were MBL-positive and0.7%carried a GES carbapenemase. In conclusion, in2018‒2020, almost all NME(97%) and most P. aeruginosa(80%) isolates from Latin America were IMR-susceptible. Continued surveillance of the in vitro activities of IMR and comparator agents against Gram-negative pathogens, and monitoring for β-lactamase changes (in particular for increases in MBLs), is warranted.